HPV Related Disease Burden and Impact of HPV Vaccine

Originally presented on May 30, 2018


Human Papilloma Virus (HPV) infections are very common and can lead to several cancers. A safe and effective vaccine exists to prevent these cancers. The optimal age for administration of the HPV vaccine is before exposure to HPV. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends administration to youth between 11-12 years of age. HPV vaccine is safe and effective in preventing disease. Even though we have an excellent preventive tool, the rates of HPV vaccination remain suboptimal.

Since this webinar aired there have been updates to the recommendations from the Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) for HPV vaccine and data related to HPV prevalence; vaccine safety, efficacy, and duration of protection; and HPV vaccine coverage estimates.

The updated ACIP recommendations were published in the Morbidity and Mortality Weekly Report on August 16, 2019. These updates included a harmonization of a catch-up recommendation for men and women through age 26 years. The recommendations also included a shared clinical decision-making recommendation for adults aged 27-45 years. The complete recommendation updates, including considerations for the shared clinical decision-making for 27-45-year-old adults.

Updated data can be found at the following CDC links:

Target Audience 

Pediatricians and family physicians, as well as nurses, physician assistants, nurse practitioners, and other medical providers who see adolescents/pre-adolescents in their practice.



HPV Related Disease Burden and Impact of HPV Vaccine


Learn More


Martin Mahoney, MD, PhD
Roswell Park Cancer Institute

Learning Outcome and Objectives

As a result of this activity, the learner will be able to enhance their knowledge and competence on the burden of diseases related to HPV infection, up-to-date information on the safety and efficacy of the HPV vaccine and challenges providers face with acceptance of the vaccine.

After this program participants will be able to:

  • Discuss the burden of clinical disease related to infection with the Human Papilloma Virus (HPV)
  • Restate the recommendations from the Advisory Committee on Immunization Practices (ACIP) on HPV vaccination for pre-teens
  • Describe the safety and efficacy of the HPV vaccine
  • Explain the challenges limiting optimal uptake of the HPV vaccine
Activity Materials
Evaluation, Post-Test and Certificate
Continuing Education Credits

Continuing Education credits for this activity expired July 31, 2022. We encourage you to fill out the evaluation as your responses help us to plan future programs.